KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $15.2 million.

  • Emergent BioSolutions' Interest Expenses rose 8313.25% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.4 million, marking a year-over-year decrease of 2374.84%. This contributed to the annual value of $71.0 million for FY2024, which is 1922.64% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Interest Expenses of $15.2 million as of Q3 2025, which was up 8313.25% from $14.7 million recorded in Q2 2025.
  • Emergent BioSolutions' Interest Expenses' 5-year high stood at $28.6 million during Q2 2023, with a 5-year trough of $7.8 million in Q2 2022.
  • Its 5-year average for Interest Expenses is $14.5 million, with a median of $14.7 million in 2025.
  • Per our database at Business Quant, Emergent BioSolutions' Interest Expenses soared by 26666.67% in 2023 and then plummeted by 5786.8% in 2024.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Interest Expenses stood at $9.0 million in 2021, then soared by 42.22% to $12.8 million in 2022, then skyrocketed by 69.53% to $21.7 million in 2023, then tumbled by 31.8% to $14.8 million in 2024, then increased by 2.7% to $15.2 million in 2025.
  • Its Interest Expenses stands at $15.2 million for Q3 2025, versus $14.7 million for Q2 2025 and $14.7 million for Q1 2025.